Kymera Therapeutics — Third Quarter 2026 Earnings Summary

Kymera Therapeutics reported positive results from the Phase 1 healthy volunteer trial of KT-579, an oral IRF5 degrader, demonstrating deep and sustained target degradation with a favorable safety profile. The company announced that the last patient completed the week 16 visit in the KT-621 Phase 2b atopic dermatitis trial, with topline data expected by the end of 2026. Additionally, the KT-621 Phase 2b asthma trial remains ongoing, and the KT-579 Phase 1b lupus trial is planned to begin in early 2027. As of September 30, 2026, the company held $1.6 billion in cash, providing a financial runway into 2029.